Yunnan Botanee Bio-Technology Group (300957) Fair Value & Analysis
Consumer Defensive · CN · Market cap 14.1B CNY
Analysis
Yunnan Botanee Bio-Technology Group (300957) currently trades at ¥32.88, while our model-based Fair Value estimate is ¥25.07 — implying the stock looks roughly 23.8% overvalued today. We read business quality at 93/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Yunnan Botanee Bio-Technology Group Co.LTD, together with its subsidiaries, engages in the research, development, production, and sale of cosmetics in China and internationally. It operates through Skin Care Products, Medical Instruments, and Makeup segments. The company offers face creams, toners, masks, serums, and lotions; and makeup products, including primers, powders, BB creams, and makeup removers. It is also involved in the research, development, production, and sale of skincare related medical devices and electronic beauty instruments comprising hyaluronic acid repair bio membranes and hyaluronic acid repair dressings used for the protection and care of skin barrier damage after minimally invasive surgery; provision of provision of supply chain management, warehouse services, capital market, and consulting services. In addition, the company offers home-use electronic radiofrequency beauty devices. Further, it offers Qiumei App, an AI system for common skin problems; and med…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.